Literature DB >> 14634104

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

Noelia Casares1, Laura Arribillaga, Pablo Sarobe, Javier Dotor, Ascensión Lopez-Diaz de Cerio, Ignacio Melero, Jesús Prieto, Francisco Borrás-Cuesta, Juan J Lasarte.   

Abstract

CD25(+) regulatory T (T reg) cells suppress the activation/proliferation of other CD4(+) or CD8(+) T cells in vitro. Also, down-regulation of CD25(+) T reg cells enhance antitumor immune responses. In this study, we show that depletion of CD25(+) T reg cells allows the host to induce both CD4(+) and CD8(+) antitumoral responses following tumor challenge. Simultaneous depletion of CD25(+) and CD8(+) cells, as well as adoptive transfer experiments, revealed that tumor-specific CD4(+) T cells, which emerged in the absence of CD25(+) T reg cells, were able to reject CT26 colon cancer cells, a MHC class II-negative tumor. The antitumoral effect mediated by CD4(+) T cells was dependent on IFN-gamma production, which exerted a potent antiangiogenic activity. The capacity of the host to mount this antitumor response is lost once the number of CD25(+) T reg cells is restored over time. However, CD25(+) T reg cell depletion before immunization with AH1 (a cytotoxic T cell determinant from CT26 tumor cells) permits the induction of a long-lasting antitumoral immune response, not observed if immunization is conducted in the presence of regulatory cells. A study of the effect of different levels of depletion of CD25(+) T reg cells before immunization with the peptide AH1 alone, or in combination with a Th determinant, unraveled that Th cells play an important role in overcoming the suppressive effect of CD25(+) T reg on the induction of long-lasting cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634104     DOI: 10.4049/jimmunol.171.11.5931

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authors:  Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire Macnamara; Poorvi Somaiya; Zekui Wu; Robin Joyce; James D Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul Richardson; Edie Weller; Kenneth Anderson; Donald Kufe; Nikhil Munshi; David Avigan
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 2.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Authors:  Christopher A Klebanoff; Hung T Khong; Paul A Antony; Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2005-02       Impact factor: 16.687

3.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.

Authors:  Abdeljabar El Andaloussi; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

4.  Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.

Authors:  Michael J Robertson; Hua-Chen Chang; David Pelloso; Mark H Kaplan
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

5.  Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases.

Authors:  Martin Grimm; Martin Gasser; Marco Bueter; Johanna Strehl; Johann Wang; Ekaterina Nichiporuk; Detlef Meyer; Christoph T Germer; Ana M Waaga-Gasser; Andreas Thalheimer
Journal:  BMC Cancer       Date:  2010-03-07       Impact factor: 4.430

Review 6.  Dendritic cell based vaccination strategy: an evolving paradigm.

Authors:  Anna C Filley; Mahua Dey
Journal:  J Neurooncol       Date:  2017-04-22       Impact factor: 4.130

7.  Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma.

Authors:  Yi-Ling Chen; Jung-Hua Fang; Ming-Derg Lai; Yan-Shen Shan
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

8.  Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes.

Authors:  Adam M Farkas; Douglas M Marvel; Olivera J Finn
Journal:  J Immunol       Date:  2013-02-18       Impact factor: 5.422

9.  Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.

Authors:  Shun Takaku; Masaki Terabe; Elena Ambrosino; Judy Peng; Scott Lonning; John M McPherson; Jay A Berzofsky
Journal:  Int J Cancer       Date:  2010-04-01       Impact factor: 7.396

10.  Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes.

Authors:  S Audia; A Nicolas; D Cathelin; N Larmonier; C Ferrand; P Foucher; A Fanton; E Bergoin; M Maynadie; L Arnould; A Bateman; B Lorcerie; E Solary; B Chauffert; B Bonnotte
Journal:  Clin Exp Immunol       Date:  2007-10-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.